Related references
Note: Only part of the references are listed.Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Manuel Piechutta et al.
ESMO OPEN (2019)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al.
CANCER CELL (2018)
Second-Line Treatment in Patients With Pancreatic Ductal Adenocarcinoma: A Meta-Analysis
Mohamad Bassam Sonbol et al.
CANCER (2017)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer
M. Ghosn et al.
MEDICAL ONCOLOGY (2012)
Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
Luigi Laghi et al.
PLOS ONE (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival
Anna Carbone et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma
Pisit Tangkijvanich et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Share Paper
